文献速递肝病

microRNA-210 靶向 MLL4 促进胆汁酸诱导的小鼠胆汁淤积性肝损伤

MicroRNA-210 Promotes Bile Acid-Induced Cholestatic Liver Injury by Targeting Mixed-Lineage Leukemia-4 Methyltransferase in Mice.
PubMed 文献 · Hepatology · 2020-02-14

该研究在小鼠中发现,胆汁酸升高时肝脏 miR-210 通过抑制 MLL4 表达,减少 SHP 和 BSEP,导致胆汁酸代谢障碍和肝损伤。沉默 miR-210 可改善胆汁淤积性肝病理,且 PBC 患者肝内 miR-210 和 KLF4 升高、核内 SHP 和 MLL4 降低。

要点

  • miR-210 直接靶向 MLL4,抑制 SHP 和 BSEP 表达,加重胆汁酸诱导的肝损伤。
  • 体内沉默 miR-210 可以 MLL4 依赖的方式改善胆汁淤积小鼠的肝病理并降低疏水性胆汁酸水平。
  • PBC 患者肝内 miR-210 和 KLF4 水平升高,而核内 SHP 和 MLL4 水平降低。

核心结论

  • 肝脏 miR-210 受 SHP 生理性调控,在胆汁淤积小鼠和 PBC 患者中升高,部分通过靶向 MLL4 促进胆汁酸诱导的肝损伤。
  • miR-210-MLL4 轴是治疗胆汁酸相关肝胆疾病的潜在靶点。

研究设计与样本

  • 研究采用胆汁淤积小鼠模型,检测 miR-210 与 MLL4 表达,并进行体内沉默 miR-210 的干预实验。
  • 在 PBC 患者肝脏样本中检测 miR-210、KLF4、SHP 和 MLL4 表达水平。

主要发现

  • 在肝 SHP 下调且肝胆汁酸水平升高的小鼠中,miR-210 是升高最显著的 microRNA。
  • MLL4 被鉴定为 miR-210 的直接靶点;过表达 miR-210 抑制 MLL4 及后续 BSEP 和 SHP 表达,导致胆汁酸代谢缺陷和炎症性肝毒性。
  • 胆汁淤积小鼠模型中 miR-210 水平升高;体内沉默 miR-210 以 MLL4 依赖方式改善胆汁酸诱导的肝病理并降低疏水性胆汁酸水平。
  • 机制上,SHP 通过抑制转录激活因子 KLF4 来抑制 miR-210 表达。
  • PBC 患者肝内 miR-210 和 KLF4 水平高度升高,而核内 SHP 和 MLL4 水平降低。

临床怎么用

  • 对于胆汁淤积性肝病,肝内 miR-210 升高可能提示 MLL4 受抑制及胆汁酸稳态失衡。
  • miR-210-MLL4 轴可作为胆汁酸相关肝胆疾病的潜在干预靶点,但尚需临床转化验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Bile acids (BAs) are important regulators of metabolism and energy balance, but excess BAs cause cholestatic liver injury. The histone methyltransferase mixed-lineage leukemia-4 (MLL4) is a transcriptional coactivator of the BA-sensing nuclear receptor farnesoid X receptor (FXR) and epigenetically up-regulates FXR targets important for the regulation of BA levels, small heterodimer partner (SHP), and bile salt export pump (BSEP). MLL4 expression is aberrantly down-regulated and BA homeostasis is disrupted in cholestatic mice, but the underlying mechanisms are unclear. APPROACH AND RESULTS: We examined whether elevated microRNA-210 (miR-210) in cholestatic liver promotes BA-induced pathology by inhibiting MLL4 expression. miR-210 was the most highly elevated miR in hepatic SHP-down-regulated mice with elevated hepatic BA levels. MLL4 was identified as a direct target of miR-210, and overexpression of miR-210 inhibited MLL4 and, subsequently, BSEP and SHP expression, resulting in defective BA metabolism and hepatotoxicity with inflammation. miR-210 levels were elevated in cholestatic mouse models, and in vivo silencing of miR-210 ameliorated BA-induced liver pathology and decreased hydrophobic BA levels in an MLL4-dependent manner. In gene expression studies, SHP inhibited miR-210 expression by repressing a transcriptional activator, Kruppel-like factor-4 (KLF4). In patients with primary biliary cholangitis/cirrhosis (PBC), hepatic levels of miR-210 and KLF4 were highly elevated, whereas nuclear levels of SHP and MLL4 were reduced. CONCLUSIONS: Hepatic miR-210 is physiologically regulated by SHP but elevated in cholestatic mice and patients with PBC, promoting BA-induced liver injury in part by targeting MLL4. The miR-210-MLL4 axis is a potential target for the treatment of BA-associated hepatobiliary disease.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Kim YC, Jung H, Seok S, et al. MicroRNA-210 Promotes Bile Acid-Induced Cholestatic Liver Injury by Targeting Mixed-Lineage Leukemia-4 Methyltransferase in Mice. Hepatology. 2020. PMID: 31549733. doi:10.1002/hep.30966

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。